• Age: 18-65 years old;

• Clinically and pathologically confirmed cT2- cT4d, or cT1c with axillary lymph node metastasis;

• Three negative type and invasive breast cancer confirmed by histopathology;

• Three negative breast cancer is defined as:

⁃ ER and PR negative (IHC nuclear staining\<10%)

⁃ Her-2 negative (IHC 0, 1+without FISH, or IHC 2+without FISH amplification)

• Clinically measurable lesions:

• Measurable lesions displayed by ultrasound, mammography, or MR (optional) within one month prior to screening;

• Organ and bone marrow function tests within 2 weeks before chemotherapy indicate no contraindications for chemotherapy:

‣ Absolute value of neutrophil count ≥ 2.0 × 109/L

⁃ Hemoglobin ≥ 100g/L

⁃ Platelet count ≥ 100 × 109/L

⁃ Total bilirubin\<1.5 ULN (upper limit of normal)

⁃ Creatinine\<1.5 × ULN

⁃ AST/ALT \< 1.5×ULN；

⁃ Urine test: Urine protein\<2+; If urine protein is ≥ 2+, the 24-hour urine protein quantification display must show protein ≤ 1g

⁃ Thyroid stimulating hormone (TSH) ≤ upper limit of normal (ULN); If there are abnormalities, T3 and T4 levels should be examined. If T3 and T4 levels are normal, they can be selected

⁃ Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 ULN, while meeting international standards Normalization ratio (INR) ≤ 1.5 ULN (not receiving anticoagulant therapy);

• Cardiac ultrasound EF value ≥ 55%;

• Women of childbearing age who tested negative for serum pregnancy test 14 days before randomization;

• ECOG score ≤ 1 point;

• Voluntary signing of informed consent